Interferon beta-1a

This is a type of medicine called interferon. It's used to help manage symptoms of a condition called multiple sclerosis. It helps the body's immune system fight off the disease.

Brand names:Avonex, Rebif
Medication

What people taking Interferon beta-1a report

Every report comes from a Lived member, sent anonymously.

Have you tried Interferon beta-1a for MS (Multiple Sclerosis)?

NameHow it went

About Interferon beta-1a

What It's For

Interferon beta-1a is an injectable medicine for adults with relapsing forms of multiple sclerosis (MS), an immune-driven disease that damages nerves in the brain and spinal cord. In the US it is sold as Avonex, injected into a muscle once a week, and Rebif, injected under the skin three times a week. Both are approved for clinically isolated syndrome (a first episode of MS-like nerve symptoms lasting at least 24 hours), relapsing-remitting MS, in which symptoms flare and then partly or fully settle, and active secondary progressive MS, a later phase in which disability builds over time while relapses or new inflammation still occur. It is a disease-modifying therapy, meaning its purpose is to reduce relapses and slow the disease rather than ease day-to-day symptoms. First approved in the US in 1996, it is one of the longest-used MS treatments, though several newer medicines reduce relapses more. Plegridy (peginterferon beta-1a) is a chemically modified, separate product with its own dosing schedule and is not interchangeable with Avonex or Rebif.

How It Works

Interferon beta is a protein the body makes naturally as part of its immune response, and interferon beta-1a is a laboratory-made version of it. In MS, it is thought to calm the immune activity that drives inflammation in the brain and spinal cord. In clinical trials, people taking it developed fewer new or active areas of damage (lesions) on MRI (magnetic resonance imaging) scans and had fewer relapses than people on placebo. Exactly how it produces these benefits in MS is not known. It does not repair damage that has already happened and does not directly relieve symptoms such as fatigue or numbness; its role is prevention.

Dosage & Administration

Both brands come as single-use prefilled syringes or autoinjector pens, and they are not interchangeable. Avonex is injected into a muscle once a week, with a usual dose of 30 micrograms. Rebif is injected just under the skin three times a week at a prescribed dose of 22 or 44 micrograms, on the same three days each week with at least 48 hours between doses (for example, Monday, Wednesday and Friday), preferably in the late afternoon or evening. Treatment usually starts at a reduced dose that is stepped up over about four weeks, which helps limit flu-like symptoms. The first injection is given under the supervision of a trained health professional, who also teaches the person or a caregiver how to inject. Rotating the injection site each time lowers the chance of skin problems, and skin that is irritated, red, bruised, infected or scarred should not be used. Both products are kept in the refrigerator and must not be frozen. A pain reliever or fever reducer on injection days, as the care team advises, can make flu-like symptoms easier to manage.

Side Effects

Flu-like symptoms are the most common side effect: chills, fever, muscle aches, weakness or headache in the hours after an injection, usually lasting about a day. They are most noticeable early in treatment and lessen or go away over time for many people. Redness, swelling, pain or bruising where the needle went in is also common, especially with Rebif. Less often, an injection site becomes infected or the skin breaks down (necrosis), and some of these cases have needed drainage or antibiotics. A site that becomes increasingly painful, hot or swollen, or that opens or drains, should be shown to the care team, as should any skin reaction that does not clear up within a few days. Blood tests often show mild rises in liver enzymes or lower blood counts. These usually cause no symptoms, which is why regular testing is part of treatment. Serious allergic reactions are rare. Trouble breathing or swelling of the lips, tongue or throat after an injection needs emergency care right away (call 911).

Interactions & Warnings

The main cautions involve mood, the liver and other health conditions, more than specific drug combinations. People who have had an allergic reaction to interferon beta should not use it, and the Avonex syringe and pen contain natural rubber latex. Depression is common in MS, and interferon beta has been linked to higher rates of depression and suicidal thoughts. New or worsening depression, thoughts of suicide, or unusual changes in thinking or behavior should be reported to the prescriber right away; stopping the medicine may be considered. Severe liver injury is rare but has progressed to liver failure in some people. Yellowing of the skin or eyes, or other signs of liver trouble, calls for prompt contact with the care team. Alcohol and other medicines that can strain the liver add to this risk and are worth discussing before starting. A history of seizures, heart failure, thyroid disease, other autoimmune conditions or low blood counts should be shared with the prescriber. Rarely, interferon beta has caused high blood pressure in the lungs (pulmonary arterial hypertension), sometimes years after starting, and a serious disorder in which small blood clots damage blood vessels and organs (thrombotic microangiopathy). New, unexplained shortness of breath or increasing fatigue is worth reporting. For people who are pregnant or planning pregnancy, large studies have not found more major birth defects after exposure in early pregnancy, though findings on miscarriage and birth weight are mixed. Small amounts reach breast milk. Both are decisions to plan with the neurologist.

What to Expect

Interferon beta-1a does not make a person feel better the way a symptom treatment does. Its benefit shows up over months and years as fewer relapses and less new activity on MRI. In the main trials, Rebif cut the number of relapses by about 30% over two years compared with placebo, and Avonex lowered the share of people whose disability worsened over two years from 35% to 22%. A 2024 Cochrane review comparing MS treatments judged that interferon beta-1a probably reduces relapses moderately, while several newer medicines reduce them more. Relapses can still happen during treatment. The first few months are often the hardest because of flu-like symptoms, which usually become more manageable. Follow-up includes regular blood tests of blood counts and liver function, periodic thyroid checks, and MRI scans at intervals the neurologist sets. Treatment is generally long term, and the neurologist uses relapses and MRI results to judge whether it is controlling the disease well enough or whether another treatment would be a better fit.

Questions to Ask Your Doctor

  1. 1.Why is interferon beta-1a a good fit for me compared with newer MS treatments that may reduce relapses more?
  2. 2.Would Avonex once a week or Rebif three times a week suit my routine better, and what does each injection involve?
  3. 3.How can I manage flu-like symptoms and injection site reactions during the first months?
  4. 4.How often will I need blood tests and MRI scans, and what results would lead us to change treatment?
  5. 5.How does this medicine fit with my plans for pregnancy or breastfeeding?

Last reviewed • Oct 2026

Educational content, not medical advice.